Bullish Stocks Trading Near 52 Week High: $NLS $EVOK $STNE

Bullish Stocks Trading Near 52 Week High: $NLS $EVOK $STNE

47
0
SHARE


The MarketWatch News Department was not involved in the creation of this content.

Aug 12, 2020 (The Market Signal via Comtex) —
*If You Own NLS, EVOK, STNE Then Click Here to Join Our Community Of Traders

The Market Signal was created as a platform to help investors, if you own (NYSE:NLS), (NASDAQ:EVOK) or (NASDAQ:STNE) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.

https://themarketsignal.com/Free-Report/NOW

(Click link above or copy, paste and hit enter in your browser for your report)

Nautilus is among the bullish stocks with increased net sales

https://themarketsignal.com/Free-Report/NLS

(Click link above or copy, paste and hit enter in your browser for your report)

Nautilus, Inc. (NYSE:NLS) is 1076.67% above its 52-Week Low, and 7.62% below its 52-Week high, the stock looks bullish.

2Q 2020

2Q 2019

Net Sales

$114 million

$59.0 million

Gross profit

$47.4 million

$17.5 million

Operating loss

$7.1 million

$85.4 million

Net loss

$5.1 million

$78.9 million

Cash, cash equivalents

$47.9 million

$11.1 million

Debt

$14.8 million

$14.1 million

Nautilus reported $114.2 million or 93.5% in net sales mainly due to strong demand for cardio and strength products. In particular, the company reported impressive sales from its connected-fitness bikes, Max Trainer(R)and treadmills. The company managed to restart and accelerate its supply chain which helped them respond to growing demand in the wake of the COVID-19 pandemic that caused high demand. Despite the increase in supply capacity however, the company fell behind in $34.2 million in unfulfilled orders.

Evoke Pharma looking bullish due to increased cash flow and reduced expenses

https://themarketsignal.com/Free-Report/EVOK

(Click link above or copy, paste and hit enter in your browser for your report)

Evoke Pharma Inc (NASDAQ:EVOK) is 632.38% above its 52-Week Low, and 7.40% below its 52-Week high, the stock looks bullish.

2Q 2020

2Q 2019

Net Loss

$7.0 million

$2.1 million

Research And Development Expenses

$5.8 million

$1.2 million

General And Administrative Expenses

$1.2 million

$0.9 million

Operating Expenses

$7.0 million

$2.1 million

Cash And Cash Equivalents

$8.0 million

Evoke Pharma reported an increase in research and development expenses during the quarter ended June 30, 2020. The increase was mainly due to $5 million in expenses incurred in June 2020 after achieving technology acquisition milestone related to FDA’s approval of Gimoti.

StoneCo Looking bullish due to robust business in 2Q 2020

https://themarketsignal.com/Free-Report/STNE

(Click link above or copy, paste and hit enter in your browser for your report)

StoneCo Ltd (NASDAQ:STNE) is 195.65% above its 52-Week Low, and 3.53% below its 52-Week high, the stock looks bullish.

StoneCo has reported robust business in the 2Q 2020 following a rebound from the COVID-19 pandemic.The company reported R$500 million increase in TPV during the quarter compared to what was reported during the same period last year. The company is once again reporting an increase in HUB volumes and client net adds and is able to maintain its normalized take rates of 1.77% and Net Margin of 22.5%. The company completed the quarter with a strong free cash flow increasing by R$264 million compared to 1Q 2020.

StoneCo reported its strongest performance from its Digital Commerce. The company has made significant investment in the sector over the last 12 months. The strategy has paid off during the pandemic as many people have turned to online shopping.

StoneCo reported 80% increase in online sales for TPV and continues to perform well with more than 94% growth in July 2020. The company’s eCommerce revenues from SMBs have gone up by almost 100% since the start of the year. This has mainly been driven by the mix shift from physical storefront sales to eCommerce. The company’s software have also performed well with revenue reaching R$100 million in 2Q20.

Please email or contact us for any edits or errors relating to this stock market news.

If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market and other Stock Market news.

We will get back to you within 24 hours.

Disclaimer

COMTEX_369296691/2662/2020-08-12T10:46:23

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

The MarketWatch News Department was not involved in the creation of this content.



Source link

LEAVE A REPLY